—
C+
C+ The full Closelooknet — membership. Open the C+ overview

BeiGene, Ltd. (ONC) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for ONC, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 53/100 · S&P 500 fund at 50, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-10-14
  • Factor regime Momentum repair attempt below trendMomentum against low volatility (SPMO / SPLV): below its 50-day trend, 89th percentile of the window, +0.6% over 20 sessions. Factor regime → 2026-10-14
  • Sovereign pressure Index -0.32 · down 0.76 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-14
How it trades on rate days beta 0.70 to TLT · on the worst bond days it fell more than the market

How it trades on rate days

How ONC has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.70 — moves strongly with bonds for every 1% move in TLT (20+ year Treasuries), BeiGene, Ltd. moved 0.70% on average · correlation 0.19 · higher than 65% of US names
  • Beta, last 3 months 0.64 about the same as over the year
  • On the 10 worst bond days −1.87% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days −1.38% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against ONC on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — BeiGene, Ltd.

ONC in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
BeiGene, now renamed BeOne Medicines AG, is an oncology company that discovers and develops cancer treatments across the United States, China and Europe. Its marketed products include a BTK inhibitor for blood cancers, a PD-1 antibody used in solid tumours and blood cancers, and separate treatments for Castleman disease and certain breast and solid-tumour cancers, alongside a wide clinical pipeline of compounds targeting different cancer pathways and partnerships with several other pharmaceutical firms.
Where it sits in the stack
BeiGene carries no seat in our index and sits outside the AI build-out stack the diary otherwise tracks. It belongs to the Healthcare sleeve of Closelooknet's universe, grouped by sector and country rather than by any layer of the build-out.
Who it is priced against
Closelooknet's peer group places it with other scored healthcare names in the same sector and country — argenx, Medpace, Globus Medical, Regeneron, Veeva Systems, Vertex Pharmaceuticals, Corcept Therapeutics and IDEXX Laboratories; the market also compares its PD-1 antibody against Merck's rival therapy.
Why Closelooknet tracks it
It carries a Closelooknet score, with momentum the strongest module and valuation the weakest; it holds no index seat and the diary has not yet quoted it.
What the diary watches
The diary watches whether clinical data from the pipeline compounds converts into approvals that could narrow the gap between the strong momentum read and the weaker valuation module.

BeiGene, Ltd. (ONC) trades on US exchanges.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 2 analyst actions on the wire · latest: price target by RBC Capital, 2026-10-08

The Street on this name

Analyst actions and the latest print for ONC from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target RBC Capital — target 459 from 450 Target raised to $459 from $450 (+34.6% to spot) 2026-10-08
  • Price target Truist — target 420 from 418 Target raised to $420 from $418 (+15% to spot) 2026-10-07

2 actions on the analyst wire since 2026-08-13: 2 target changes. Analyst wire → · Earnings wire →

Dividends and capital return no distribution in twelve months

Dividends and capital return

What ONC pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Share count +7.8% in FY2025 511 m USD of stock-based compensation in the year

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-10-15

Quick answers

What is BeiGene, Ltd. (ONC)?

BeiGene, Ltd. trades as ONC on the US exchange (US) in the Closelooknet research universe, as of the registry build of 2026-10-15.

Is ONC in a Closelooknet index?

Not currently — BeiGene, Ltd. is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-10-15.

Where does ONC trade against its moving averages?

Pullback inside an uptrend stack: Trades -2% vs the 50-day and +9.2% vs the 200-day average, 8.8% below the 52-week high and +38.4% off the 52-week low; a golden cross printed 36 sessions ago. Computed from daily closes. As of 2026-10-14 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does BeiGene, Ltd. compare with its peers?

Against its peer group (Biotechnology · US), BeiGene, Ltd. (ONC) sits 8.8% below its 52-week high, 2.0% below its 50-day average; Halozyme Therapeutics Inc (HALO) is 2.0% below, argenx NV ADR (ARGX) is 23.7% below, Krystal Biotech Inc (KRYS) is 13.6% below. Put any of them next to ONC in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does BeiGene, Ltd. trade when bond yields rise?

Over the past year BeiGene, Ltd. had a beta of 0.70 to TLT, the long-dated Treasury fund — it moves strongly with bonds, higher than 65% of US names. On the 10 sessions in which long bonds fell most it moved −1.87% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What does BeiGene, Ltd. do?

BeiGene, now renamed BeOne Medicines AG, is an oncology company that discovers and develops cancer treatments across the United States, China and Europe. Its marketed products include a BTK inhibitor for blood cancers, a PD-1 antibody used in solid tumours and blood cancers, and separate treatments for Castleman disease and certain breast and solid-tumour cancers, alongside a wide clinical pipeline of compounds targeting different cancer pathways and partnerships with several other pharmaceutical firms. Closelooknet's peer group places it with other scored healthcare names in the same sector and country — argenx, Medpace, Globus Medical, Regeneron, Veeva Systems, Vertex Pharmaceuticals, Corcept Therapeutics and IDEXX Laboratories; the market also compares its PD-1 antibody against Merck's rival therapy.

Where does BeiGene, Ltd. sit in the AI build-out?

BeiGene carries no seat in our index and sits outside the AI build-out stack the diary otherwise tracks. It belongs to the Healthcare sleeve of Closelooknet's universe, grouped by sector and country rather than by any layer of the build-out. It carries a Closelooknet score, with momentum the strongest module and valuation the weakest; it holds no index seat and the diary has not yet quoted it.

Does BeiGene, Ltd. pay a dividend?

No cash distribution shows in BeiGene, Ltd.’s price series over the last three years. The share count rose 7.8% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on BeiGene, Ltd. recently?

The most recent analyst action on BeiGene, Ltd. on the Closelooknet wire is a price target by RBC Capital on 2026-10-08 (target 459 from 450). 2 actions on the analyst wire since 2026-08-13: 2 target changes. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for ONC, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.